Sen. Mike Braun

Maddy summaryThis bill amends federal law to ensure military offenses under the Uniform Code of Military Justice (UCMJ) are treated equally with civilian offenses in child exploitation cases. It updates references throughout Title 18 to replace outdated phrasing (like "section 920 of title 10") with "the Uniform Code of Military Justice" in key provisions. The changes directly affect military personnel facing federal prosecution for child exploitation, ensuring their cases align with civilian legal standards. The bill makes no new penalties but clarifies that UCMJ offenses are considered equivalent to state offenses under federal sentencing guidelines.

Maddy summaryThis bill establishes a 2-year pilot program (starting January 2025) to test predictive algorithms that assess risk in Medicare payments for durable medical equipment (like wheelchairs) and lab tests. It applies only to Medicare beneficiaries who have opted in to receive electronic Medicare Summary Notices. The program uses algorithms to flag high-risk transactions based on factors like unusual billing patterns or new provider ownership, but requires human review before suspending payments. Beneficiaries can opt out anytime, and the system must notify them about risk scores and provide a 3-month period of electronic notices if a transaction is flagged.

Maddy summaryThe Medical Device Nonvisual Accessibility Act of 2024 requires manufacturers of certain home-use medical devices - such as blood pressure monitors, sleep apnea machines, and in-home chemotherapy equipment - to design user interfaces that are accessible to blind or low-vision individuals. This applies to class II or III devices with screens or mobile apps that are cleared for home use, not solely for healthcare providers. The law mandates that interfaces must provide equal privacy, independence, and ease of use for blind or low-vision users as for sighted users, with manufacturers able to request waivers for "fundamental alteration" or "undue hardship" (e.g., excessive cost). The Secretary of Health and Human Services must develop implementing regulations within two years and provide manufacturer training.

Maddy summaryThis bill restricts health savings account (HSA) and similar account reimbursements for abortions, except in specific cases. It amends tax code provisions to exclude most abortion expenses from qualified HSA distributions, Archer MSAs, health flexible spending accounts, health reimbursement arrangements, and retiree health accounts. Exceptions allow reimbursement for abortions resulting from rape or incest, or when a physician certifies the pregnancy poses a life-threatening physical condition to the woman. The changes apply to expenses incurred after December 31, 2024. The bill directly affects individuals using these tax-advantaged health accounts seeking abortion coverage.

Maddy summaryS 3604, the Safeguarding Charity Act, clarifies that tax exemptions under IRS Section 501(c) or 401(a) do not count as "Federal financial assistance" for regulatory purposes. The bill amends U.S. Code to explicitly exclude tax-exempt status from definitions of federal assistance in all federal laws, rules, or regulations. This directly affects tax-exempt charities and nonprofits that rely on IRS 501(c) status, ensuring their tax exemptions are not treated as government funding when applying federal programs or requirements.

Maddy summaryThis bill amends the federal tax code to exclude abortion costs from medical expense deductions. It prevents taxpayers from deducting abortion expenses on their federal income tax returns, directly affecting individuals who pay for abortions. The bill includes exceptions for abortions needed to save a woman's life (due to pregnancy-related conditions), or in cases of rape or incest, as certified by a physician. The policy change applies to taxable years starting after the bill's enactment. This alters how abortion expenses are treated for tax purposes but does not affect access to abortion services.

Maddy summaryThis bill requires federal agencies to publicly report detailed spending data related to China in annual budget submissions. It mandates that agencies disclose, for each fiscal year, all funds provided to Chinese entities (including the Chinese government, Communist Party, Chinese campuses of U.S. universities, and China-based entities), funds used in U.S.-China partnerships, and funds for U.S. employees working in China. The reports must disaggregate spending by specific recipients and projects, covering all relevant accounts and including 10 years of historical data in the first submission. This transparency measure applies to all federal departments and agencies managing such funds.

Maddy summaryThe Mandatory Removal Proceedings Act (S 3587) requires the Secretary of Homeland Security to immediately start removal proceedings for non-citizens whose visas are revoked due to security concerns. It removes the previous discretion of the Secretary to decide whether to proceed, mandating automatic removal when a visa revocation occurs under specific security grounds outlined in immigration law. This policy directly affects foreign nationals with visas revoked on security-related grounds, such as those posing threats to national security. The bill changes the procedural step after visa revocation without altering the grounds for revocation itself.

Maddy summaryS 3583 (A bill to address patent thickets) limits patent holders from asserting multiple patents against generic drug and biosimilar manufacturers in infringement lawsuits. It restricts a plaintiff to one patent per "Patent Group" (defined as commonly owned patents that avoid double patenting) when suing companies developing generic drugs under FDA's 505(b)(2)/505(j) pathways or biosimilars under PHS Act 351(k). The bill prohibits filing additional lawsuits for the same Patent Group against the same generic or biosimilar company. This directly affects pharmaceutical companies developing affordable alternatives and patent holders seeking to enforce patents against them.

Maddy summaryThis bill defines what qualifies as an "egg" or "egg product" under federal law, requiring that only products meeting specific criteria (like being the reproductive output of poultry with a calcium shell) can use egg-related terms in marketing. It prohibits labeling non-egg products - such as plant-based alternatives - with terms like "egg" or "egg product" if they don’t meet these definitions. The FDA must issue enforcement guidance within 180 days of the bill’s enactment to implement these rules. This directly affects food manufacturers, retailers, and consumers by ensuring labeling accurately reflects product content, particularly for those with dietary needs or allergies.